Kyntra Bio, Inc. (NASDAQ:KYNB) — Market Cap & Net Worth
Market Cap & Net Worth: Kyntra Bio, Inc. (KYNB)
Kyntra Bio, Inc. (NASDAQ:KYNB) has a market capitalization of $27.53 Million ($27.53 Million) as of May 22, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24086 globally and #5057 in its home market, demonstrating a -0.86% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kyntra Bio, Inc.'s stock price $6.94 by its total outstanding shares 4048112 (4.05 Million). Analyse KYNB operating cash flow to see how efficiently the company converts income to cash.
Kyntra Bio, Inc. Market Cap History: 2026 to 2026
Kyntra Bio, Inc.'s market capitalization history from 2026 to 2026. Data shows growth from $28.09 Million to $28.09 Million (0.00% CAGR).
Kyntra Bio, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kyntra Bio, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KYNB by Market Capitalization
Companies near Kyntra Bio, Inc. in the global market cap rankings as of May 22, 2026.
Key companies related to Kyntra Bio, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.03 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #414 globally with a market cap of $66.20 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #577 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #598 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.03 Billion | $433.54 |
| #414 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $66.20 Billion | $642.59 |
| #577 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #598 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Kyntra Bio, Inc. Historical Marketcap From 2026 to 2026
Between 2026 and today, Kyntra Bio, Inc.'s market cap moved from $28.09 Million to $ 28.09 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $28.09 Million | -- |
End of Day Market Cap According to Different Sources
On May 22nd, 2026 the market cap of Kyntra Bio, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $27.53 Million USD |
| MoneyControl | $27.53 Million USD |
| MarketWatch | $27.53 Million USD |
| marketcap.company | $27.53 Million USD |
| Reuters | $27.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more